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To assess the prevalence and clinical features of neurologic involvement in patients with acute
hepatitis E virus (HEV) infection in Southern Switzerland.
Methods
Among 1,940 consecutive patients investigated for acute hepatitis E, we identified 141 cases of
acute of HEV infection (anti-HEV immunoglobulin M and immunoglobulin G both reactive
and/or HEV RNA positive) between June 2014 and September 2017. Neurologic cases were
followed up for 6 months. We compared patients with and without neurologic symptoms.
Results
Neurologic symptoms occurred in 43 acute HEV cases (30.4%) and consisted of neuralgic
amyotrophy (NA, n = 15, 10.6%) and myalgia (n = 28, 19.8%). All NA cases were immuno-
competent. Men had higher odds (OR = 5.2, CI 1.12–24.0, p = 0.03) of developing NA after
infection with HEV, and in 3 couples simultaneously infected with HEV, only men developed
NA. Bilateral involvement of NA was predominant (2:1) and occurred only in men. Seven NA
cases were viremic (all genotype 3), but HEV was undetectable in their CSF. In the acute phase
of NA, 9 patients were treated with intravenous immunoglobulin and 4 with prednisone,
reporting no side effects and improvement in pain and strength. Myalgia occurred both without
(n = 16) or with (n = 12) concomitant elevated serum creatinine kinase. Seven cases with
myalgia in the shoulder girdle did not have muscle weakness (“forme fruste” of NA).
Conclusions
Neurologic symptoms occurred in one-third of acute HEV infections and consisted of NA and
myalgia. NA seems to occur more frequently in men infected by HEV and has a predominant
(but not exclusive) bilateral involvement.
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Hepatitis E virus (HEV) is one of the most common causes of
acute hepatitis in the world,1 and its incidence is increasing.2
In developed countries, infection is mainly due to ingestion of
contaminated raw meat of pork or game.1 In Switzerland,
HEV seroprevalence is estimated to be approximately 20% in
healthy blood donors, depending on age and geographical
area, being the highest (35%) in Southern Switzerland.3
Most cases of HEV infection in humans are asymptomatic,1
whereas some lead to acute hepatitis and only a minority to
extrahepatic manifestations.4,5 Intriguingly, the most com-
mon extrahepatic features of HEV infection are neurologic
diseases.6–8 These mainly include acute dysimmune neu-
ropathies such as neuralgic amyotrophy (NA)9 and Guillain-
Barré syndrome (GBS),10 Bell palsy,11 myalgia/myositis,12
encephalitis,13 transverse myelitis,14 and, more recently,
myasthenia gravis.15
Recent cohort and case-control studies (mainly, but not ex-
clusively from Europe) showed that 5%–11% of GBS
cases10,16–18 and 10% of patients with NA9 were infected by
HEV at disease onset. Recent HEV infection was found in
2.4% of consecutive nontraumatic neurologic patients.19 On
the other hand, a variable proportion of confirmed cases of
acute HEV infection (between 5% and 22%, depending on the
geographical area and study type) have been reported to de-
velop neurologic symptoms.20–22
Objectives
The aim of our study was to further explore the relationship
between HEV infection and neurologic complications in
a well-defined geographical area.
Methods
Subjects
We prospectively studied consecutive adult patients di-
agnosed with acute HEV infection between June 1, 2014,
and September 30, 2017. The study was conducted in
Ticino, a region of Southern Switzerland with a population
of approximately 350,000 inhabitants. During the study
period, all laboratories in Ticino centralized the testing of
samples for HEV to the Laboratory of Microbiology
EOLAB, Bellinzona.
Aims
1. To assess the prevalence of neurologic manifestations
occurring in subjects with acute HEV infection living in
Ticino
2. To compare characteristics of patients with acute HEV
infection with and without neurologic involvement and
clinically characterize these neurologic manifestations
Inclusion criteria
The diagnostic criteria for acute HEV infection were de-
tection of 9,10
1. serum anti-HEV immunoglobulin M and anti-HEV
immunoglobulin G both reactive and/or
2. HEV RNA+ documented in serum and/or feces by
reverse transcription polymerase chain reaction
Subjects with false-positive serologic results (low HEV IgM
positivity, not confirmed by a repeated serologic test after 1
month) or with any other concomitant acute infections or
vaccinations and patients with any other causes of acute
hepatitis were excluded.
Clinical data
Demographic (age and sex) and clinical data (immunosup-
pression status, alanine aminotransferase [ALT], and bilirubin
levels) were collected. All patients were screened for neurologic
symptoms and/or signs by the treating physician and referred
for neurologic evaluation at the Neurocenter of Southern
Switzerland, Lugano, on suspicion of neurologic involvement.
Such patients underwent a full neurologic examination and had
a series of investigations to exclude concomitant infections
(hepatitis A virus, hepatitis B virus, hepatitis C virus, human
immunodeficiency virus, cytomegalovirus, Epstein-Barr virus,
Borrelia burgdorferi, and Treponema pallidum) and additional
tests as clinically appropriate (antinuclear antibodies [ANA],
antidouble strand DNA antibodies, extractable nuclear antigen
antibodies, antineutrophil cytoplasmic antibodies screening,
antiganglioside antibodies tests, lumbar puncture, brachial
plexus, brain and spinal MRI, and electrodiagnostic studies)
and were all followed up for at least 6 months thereafter.
NA was defined by van Eijk et al.23 and GBS according to
NINDS criteria.24 Myalgia was defined as pain in the muscles
present at rest, neither preceded by trauma or physical exer-
cise nor triggered by medication, with a minimal intensity of
5/10 on the visual analogue scale, independent of the creat-
inine kinase (CK) level.
Virologic analyses
Sera from patients with suspected HEV infection were tested
for HEV IgG and IgM with Dia.Pro kits (Diagnostic Biop-
robes srl, Italy). Real-time quantitative HEV RNA reverse
transcriptase polymerase chain reaction and HEV genotype
determination were performed according to Fraga et al.25
Glossary
ALT = alanine aminotransferase; ANA = antinuclear antibodies; CK = creatinine kinase; GBS = Guillain-Barré syndrome;
HEV = hepatitis E virus; IFN = interferon; IVIg = intravenous immunoglobulin; NA = neuralgic amyotrophy.
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Statistical analysis
Continuous variables were described by median with inter-
quartile ranges and categorical variables by counts and per-
centages. Age, sex, immunosuppression status, and liver
function parameters were tested for potential association with
neurologic disease status using logistic regression with OR
and 95% CI estimation. Statistical significance was set at
2-sided p values < 0.05. Data were analyzed with the R sta-
tistics package (r-project.org/).
Ethical aspects
The study was approved by the local Ethics Committee of
Ticino (CE 2932), and written informed consent was
obtained from the participants in the study. Authorization has
been obtained for disclosure of any recognizable person in
videos.
Data availability
Anonymized data that are not published in the current study
will be shared on request from any qualified investigator.
Results
Among 1,940 patients investigated for acute HEV infection,
150 cases were identified (figure 1). Nine were excluded be-
cause of false-positive serologic results (n = 5), concomitant
CMV infection (n = 3; one of these cases had GBS), or recent
vaccination (n = 1; this patient had encephalomyelitis). The
final analysis included 141 HEV IgM- and IgG-positive cases;
35 (25%) were also HEV RNA positive, and all were HEV
genotype 3 when sequencing was successful.
Reasons for HEV testing were acute hepatitis with (n = 55,
39%) or without (n = 34, 24%) jaundice, unexplained in-
creased liver enzyme resulting from screening of clinically
asymptomatic patients (n = 7, 5%), acute kidney failure (n = 2,
1%), and neurologic symptoms (n = 43, 30.4%) consistent
with NA (n = 15, 10.6%) or myalgia (n = 28, 19.8%). Some of
these cases have been reported in previous studies with dif-
ferent aims.25,26
Age, sex, immunosuppression status, ALT, and bilirubin levels
of the overall cohort at onset are summarized in table 1. The
median age was 59 years, with a nonsignificant predominance
of men (59% vs 41%). Compared with patients without
neurologic manifestations, those with neurologic involvement
were younger (OR = 0.97, CI 0.94–0.99, p = 0.01). NA oc-
curred more frequently in men (OR = 5.2, CI 1.12–24.0, p =
0.03), whereas myalgia occurred less frequently in men (OR =
0.36, CI 0.15–0.86, p = 0.02). We did not identify any dif-
ferences in immunosuppression status, ALT, or serum bili-
rubin levels between patients with and without neurologic
symptoms.
Within the group with neurologic complications, we observed
3 couples (husband and wife) simultaneously infected by
HEV, probably from a common food source. Although all
husbands developed bilateral NA, their wives were asymp-
tomatic (n = 2) or had transient myalgia (n = 1).
Neuralgic amyotrophy
NA cases appeared to cluster in rural areas (figure 2) and not
in the city of Lugano, the most populated area (70,000
inhabitants).
Shoulder pain was often described as “like a knife penetrating
muscles” and was severe enough to prompt patients to attend
the emergency ward even in the middle of the night. Neu-
rologic involvement in HEV-NA was bilateral (although
asymmetrical) in 10 men and predominantly located in the
upper plexus.26 Scapular winging from long thoracic nerve
damage was a recurrent feature (10/15, 67%) observed at
disease onset27 (figure 3A). In 3 cases, amyotrophy had a clear
patchy distribution, suggesting that nerve damage occurred at
the fascicular level23,28 (figure 3B).
The laboratory and clinical data of the HEV-NA cases are
summarized in table 2. None of the patients with HEV-NA
were immunosuppressed at the time of infection. Lumbar
puncture was performed in 6 of 10 NA cases with bilateral
involvement. One patient with extended neurologic damage
(involving the brachial plexus bilaterally, lumbosacral plexus,
and trigeminal nerve) had an increased CSF cell count (55
cells/mcl) and protein level, whereas isolated albumin-
cytologic dissociation was found in 2 other bilateral HEV-
NA cases.
Viral HEV RNA gt-3 was detected in the serum of 7 of 8 NA
cases tested within 1 week fromonset. In 5 of these, concomitant
CSF was collected on the same day, but none contained HEV
RNA. Serum immunofixation showed a monoclonal IgM peak
(κ or λ) in 5 bilateral NA cases tested in the acute phase, which
disappeared within a fewweeks. ANA antibodies were positive at
low titer (1/80–1/160) in 5 of 10 bilateral HEV-NA cases.
Figure 1 Flowchart of the study design
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Serum antiganglioside antibodies (GM1, GM2, GD1a, GD1b,
and GQ1b) and anti-myelin-associated glycoprotein were neg-
ative in all bilateral HEV-NA cases.
Electrodiagnostic studies were performed within 1 month in all
HEV-NA cases. Motor and sensory nerve conduction studies
were normal, as previously reported by others.29 Needle elec-
tromyography showed in all cases in the acute phase a reduced
(neurogenic) recruitment pattern in affected shoulder girdle
muscles and also signs of acute denervation (fibrillation
potentials and positive sharp waves) in 10 cases (66%), which
disappeared within 6 months.
Table 1 Study population characteristics
All (n = 141)
Neurologic cases (n = 43)
Nonneurologic cases
(n = 98)NA (n = 15) Myalgia (n = 28)
Age (median) (IQR) 59 (48–70) 51 (45–61) 53 (43–62) 60 (49–73)
Male 83 (59%) 13 11 59
Female 58 (41%) 2 17 39
Immunosuppression 16 0 3 13
ALTa (median) (IQR) 175 (56–741) 240 (100–957) 88 (28–394) 211 (57–938)
Bilirubina (median) (IQR) 20 (13–53) 19 (14–35) 14 (11–17) 24 (14–74)
HEV RNA in serum (all gt3) 35/64 tested 7/12 7/12 24/40
Abbreviations: ALT = alanine aminotransferase (IU/L; normal < 50), bilirubin (μmol/L, normal <19); gt3 = genotype 3; HEV = hepatitis E virus; IQR = interquartile
range; NA = neuralgic amyotrophy.
a At disease presentation.
Figure 2 Location of Ticino in Switzerland and geographical distribution of HEV-NA cases
The residence of the 15 NA cases is approximated by blue dots. The population density in the area is shown in different colors in a red scale (legends on the
left). Most of the cases were not located in urban but in rural areas (this map has been obtained from data of the Federal Office of Topography [Swisstopo]).
HEV = hepatitis E virus; NA = neuralgic amyotrophy.
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Two patients with unilateral HEV-NA did not receive any
immunomodulatory treatment because they had minor weak-
ness. Regarding the remaining HEV-NA cases, they were
treated within 10 days from onset either with intravenous im-
munoglobulin (IVIg) 0.4 g/kg/d for 5 days in cases of bilateral
involvement (n = 9) or with oral prednisone 60 mg/d × 7 days,
with tapering in 7 days in cases of unilateral weakness (n = 4),
as previously reported in a retrospective study.30
All patients with HEV-NA receiving these immunomodula-
tory treatments reported both reduction in pain and im-
provement in shoulder mobility and strength within 7–10
days (video 1 for steroids, video 2 for IVIg). All patients
received supportive physiotherapy over the course of their
illness. Four cases received pregabalin 150 mg/d for 2–3
months to treat neuropathic pain. Regarding long-term re-
covery, 3 heavymanual workers with bilateral HEV-NA had to
stop their job for more than 6 months because of early fati-
gability of affected arms.
Myalgia
Myalgia occurred in 28 cases, both with (n = 12) and without
(n = 16) concomitant elevated (>200 U/L) serum CK. The
highest CK value in our patients was 4.100 U/L. The pain was
often unbearable, was more intense in the night, and had clear
neuropathic features characterized by “burning,” “squeezing,”
“electric shock,” and “lancinating” sensations (DN4 score
> 4).31
Muscle pain disappeared spontaneously after 2 or 3 weeks in
all cases and was either diffuse (n = 21) or located selectively
in the shoulder girdle (“forme fruste” of NA, n = 7). We
defined “forme fruste” of patients with NA with severe, neu-
ropathic shoulder pain (unilateral or bilateral) lasting not
more than 72 hours, which was not followed by limb weak-
ness. Three of these patients with “forme fruste” of NA had an
increased CK level (up to 500 U/L), and 5 underwent elec-
tromyography studies which were normal. None of these
patients received brachial plexus MRI or muscle biopsy.
Discussion
The findings of our study suggest that neurologic symptoms
in patients with acute HEV infection may be more common
than previously estimated. Retrospective studies organized in
hepatological settings described neurologic illness in
5%–7.5% of patients presenting with clinical or subclinical
hepatitis.4,20,21 However, more recent findings from a pro-
spective study performed in France22 showed that 22% of
immunocompetent HEV cases had neurologic symptoms,
which is more in line with our findings.
There are several possible reasons to explain why we observed
so many cases of neurologic injury associated with HEV. One
possibility is that neurologic damage could be related to the
neurotropism of the circulating HEV viral strains in Southern
Switzerland. An alternative explanation could be that the local
awareness about HEV infection prompted physicians to test
for HEV cases with unexplained abnormally high serum
aminotransferases, especially in case of pain. Finally, it is also
likely that in previous studies, myalgia was not identified or
classified as a neurologic symptom. This is especially true for
the “forme fruste” of NA,26 an entity that is currently over-
looked also by neurologists because of late (or absent)
referral.
None of our neurologic cases was jaundiced, and in most the
liver function test abnormality was modest (ALT < 1,000 IU/
L). In particular, NA appeared to be strongly associated with
HEV, occurring in 11% of acute HEV cases (especially in
men) with a predominant (2:1) bilateral involvement. It is
noteworthy that all 12 bilateral NA cases diagnosed at the
Neurocenter in Lugano in the past 3 years were men with
acute HEV infection. These findings confirm previous
observations that the predominant clinical phenotype of
HEV-associated NA is that of bilateral involvement of the
brachial plexus.26
It is currently unclear why after exposure to the same in-
fectious agent individuals develop different clinical manifes-
tations. We identified sex as a possible risk factor because men
with HEV had higher odds for NA. Our observation of 3
couples infected simultaneously with HEV is similar to a case
report32 more than 30 years ago, even before HEV discovery.
Within an Italian family, 3 members simultaneously de-
veloped bilateral NA 1 week after a short fever, but the 2
brothers developed the full picture of NA (with scapular
Figure 3 Clinical picture of HEV-NA
(A) In bilateral HEV-NA cases (above), winged scapula (black arrows) is re-
current and often asymmetrical. (B) In unilateral HEV-NA cases (below),
amyotrophy is often very focal, affecting one muscle and sparing the
neighboring muscle (left: involvement of the upper trapezius = green arrow,
deltoid spared; right: brachialis muscle affected = red arrow, biceps brachii
spared). HEV = hepatitis E virus; NA = neuralgic amyotrophy.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 1 | January 2020 5
winging), whereas the mother suffered only from pain and
had no weakness. Moreover, larger epidemiologic studies26
have shown that NA occurs more commonly in men (ratio 2:
1), and also in a recent French study,22 5 of 6 HEV-NA cases
were men. The reason(s) why HEV-associated NA is more
common in men is unclear, but sex hormones are known to
influence innate33 and adaptive34,35 immune response during
viral infection. The immune response to virus is regulated by
interferons (IFNs), and IFN treatment can induce bilateral
NA.36
Regarding the host immune status, another factor that could
potentially influence clinical presentation, it is important to note
that all our 15 HEV-NA cases were immunocompetent.
When tested within 1 week from onset, 7 of 8 HEV-NA cases in
our cohort were viremic, as previously described.9,20,21,26 By
contrast, HEV is much less commonly found in the CSF, and in
the literature, there are only 2 reported NA cases where HEV
RNA has been demonstrated in the CSF.37,38 None of the 5
patients with NA who were viremic and received the lumbar
puncture on the same day of serum collection showed HEV
RNA in the CSF. Taken together, these data suggest that HEV is
cleared very early in the CSF and/or that neurologic injury is
mediated by mechanisms more complex than direct viral in-
vasion, e.g., through immune-mediated mechanisms. Recent
studies showed that intrathecal synthesis of anti-HEV IgM can
occur in HEV-NA cases.38 Although none of our patients with
NA or myalgia underwent a biopsy, it is tempting to speculate
Table 2 Clinical features of HEV-related NA
HEV-NA Total n = 15 Bilateral n = 10 Unilateral n = 5
Age (median) (IQR) 51 (61–45) 58 49
Male 13 (86%) 10 3
Female 2 (14%) 0 2
Hospitalization 12 7 5
NRSa (median) at onset 8 (9.5–8) 8 10
EMG spontaneous activity (fibrillations, positive waves)
at 1 month
10 (67%) 6 4
HEV RNA + (serum)b
All gt-3
7 7 0
HEV RNA+ (CSF)c 0 0 n.a.
Lumbar puncture 6 6 0
CSF WBC >10/mm3 1/6 1/6 n.a.
CSF protein increase 3/6 3/6 n.a.
ALTa (median) 240 (100–957) 579 178
ALPa (median) 126 (80–174) 126 128
Bilirubina (median) 19 (14–35) 52 13
GGTa (median) 144 (39–203) 178 55
ANA positivity 5 5 0
ENA positivity 0
Antiganglioside antibodies 0
IgM monoclonal peak in serum 5 5 0
IVIg 0.4 g/kg × 5d 9 8 1
Oral prednisone 60 mg/d × 7 d, tapering in 7 d 3 1 2
No immunomodulatory treatment 2 0 2
Abbreviations: ALKP = alkaline phosphatase; ALT = alanine aminotransferase; ANA = antinuclear antibodies; EMG = electromyography; ENA = extractable
nuclear antigen; GGT = gammaglutamyl transferase; HEV = hepatitis E virus; IQR = interquartile range; IVIg = intravenous immunoglobulin;WBC =white blood
count.
Normal range: bilirubin < 19 μmol/L; ALT < 41 IU/L; ALKP = 40–129 IU/L; GGT < 61 IU/L; CSF analysis: WBC < 5; protein <0.40 g/L.
a At disease presentation.
b Tested within 7 days from disease onset.
c CSF was collected the same day as the serum used for HEV RNA testing.
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that antibody/immunocomplexes deposition in the peripheral
nerve andmuscle tissuesmight contribute to neurologic damage.
Similar mechanisms have previously been shown to be operative
in cryoglobulinemia39 and other extrahepatic complications re-
lated to HEV.40 Unfortunately, in our study, cryoglobulins were
not tested, so this hypothesis remains speculative.
According to our model of immune-mediated pathogenesis,
we treated patients with NA in the acute phase with IVIg or
steroids. Both treatments were always discussed with the
hepatologist and tailored for each patient based on safety
reasons (mainly the viremic state) and individual comorbid-
ities (e.g., diabetes). We chose IVIg for bilateral cases because
these patients were usually viremic (7/10), and we wanted to
avoid worsening of viral replication/hepatitis by using high-
dose steroids. We instead preferred oral steroids for unilateral
cases who were usually referred with a longer delay and were
never viremic (0/5). Treatment of patients with HEV-NAwas
however beyond the scope of this study, and no firm con-
clusions can be drawn from our observational study. How-
ever, it is worthwhile to note that all patients reported
improvement of neuropathic pain, shoulder girdle muscle
strength, and scapular dyskinesia within 7–10 days (videos 1
and 2) and that both IVIg and steroids were well tolerated.
None of the viremic HEV-NA cases developed chronic HEV
infection or experienced an increase in transaminase levels.
Regarding GBS, we excluded 2 cases of GBS who were reactive
for both HEV IgM and IgG because they did not fulfill our
inclusion criteria. The first of these patients had concomitant
CMV infection, as reported by other authors,18 raising the
question whether these observations were because of only
crossreactivity or true co-occurrence of infections. Our second
case of HEVGBS was excluded only because the diagnosis was
made 3 months after study termination. This was an 80-year-
old woman with an axonal form (AMSAN) of GBS. She de-
veloped acute tetraparesis, bilateral facial diplegia, and bulbar
symptoms with a need for tracheotomy and assisted ventilation
(GBS disability scale = 5). She received 2 cycles of intravenous
immunoglobulins and recovered completely after 6 months.
Our clinical experience suggests that sometimes the clinical dif-
ferences between a bilateral form of NA and a pharyngeal-
brachial-cervical variant of GBS can bemodest, and some patients
might be classified either asNAorGBS (see e.g., case 3 of ref. 18).
There are some limitations to our study. First is the issue of case
ascertainment bias because our study population represents only
a limited proportion of all acute HEV-infected cases. Only
a minority of patients with HEV develop symptoms or are
detected through an elevated serum aminotransferase level, and
most infections are never diagnosed. Moreover, because the
referral to the Neurocenter was based on the treating physician’s
decision, it cannot be excluded that neurologic cases with minor
symptoms were missed. Second, our study population mostly
included immunocompetent patients in the acute phase of HEV
infection, and we did not focus on chronic cases of HEV
infection. The frequency and the clinical features of neurologic
complications in immunosuppressed HEV-infected cases (e.g.,
transplant recipients) could be different from what we observed,
yet 1 study showed that neurologic injury was less common in
immunosuppressed patients.22 Finally, our observations should
be confirmed in different geographical regions. The clustered
distribution and high number of NA cases observed might be
explained by viral factors such as a special neurotropism.Of note,
the viral strain most frequently isolated in Switzerland (3s)
appears to be unique,41,42 but correlations between viral strains
and clinical symptoms are currently lacking, and larger collabo-
rative studies are underway in Europe (e.g., HEVnet, rivm.nl/en/
hevnet) to address this issue.
In conclusion, neurologic symptoms occurred in approximately
one-third of documented acuteHEV cases and consisted of NA
and myalgia. HEV-NA seems to occur more frequently in men
and was bilateral in two-thirds of the cases. Larger prospective
epidemiologic studies on the potential role of HEV as a trigger
of (neurologic) autoimmunity43 and randomized-controlled
trials on the treatment of HEV-NA are warranted.
Acknowledgment
The authors are grateful to Ente Ospedaliero Cantonale,
Neuromuscular Research Association of Basel, and Baasch-
Medicus Stiftung of Zurich for funding support; Klaus Toyka
for helpful comments on the manuscript; Swiss Federal Office
of Topography (Swisstopo) and Wabern for providing maps
and data of figure 2; and Mario Uhr (Synlab Ticino) for
collaborating on data collection.
Study funding
ABREOC 2016 (Ente Ospedaliero Cantonale funding) to PR
and CG; Neuromuscular Research Association Basel (NERAB)
2016 to PR; Baasch-Medicus Foundation 2018 to PR.
Disclosure
All authors report no conflicts of interest to the present
project. Go to Neurology.org/NN for full disclosures.
Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation
September 16, 2019. Accepted in final form October 11, 2019.
Appendix Authors









the study, major role
in the acquisition of
data, analysis of the








Author Major role in the
acquisition of data
and analysis of the
data
Continued
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 1 | January 2020 7
References
1. Kamar N, Izopet J, Pavio N, et al. Hepatitis E virus infection. Nat Rev Dis Primers
2017;16:17086.
2. Capai L, Falchi A, Charrel R. Meta-analysis of human IgG anti-HEV seroprevalence in
industrialized countries and a review of literature. Viruses 2019;11:E84.
3. Charrel C, Widmer N, Hotz M, et al. Current hepatitis E virus seroprevalence in Swiss
blood donors and apparent decline from 1997 to 2016. Euro Surveill 2018;23:
1700616.
4. Woolson KL, Forbes A, Vine L, et al. Extra-hepatic manifestations of autochthonous
hepatitis E infection. Aliment Pharmacol Ther 2014;40:1282–1291.
5. Kamar N,Marion O, Abravanel F, Izopet J, Dalton HR. Extrahepatic manifestations of
hepatitis E virus. Liver Int 2016;36:467–472.
6. Dalton HR, Kamar N, van Eijk JJ, et al. Hepatitis E virus and neurological injury. Nat
Rev Neurol 2016;12:77–85.
7. Mclean BN, Gulliver J, Dalton HR. Hepatitis E virus and neurological disorders. Pract
Neurol 2017;17:282–288.
8. Dalton P, Norton B, van Eijk J, Dalton HR. Non-traumatic neurological injury and
hepatitis E infection. Expert Rev Anti Infect Ther 2018;16:255–257.
9. van Eijk JJ, Madden RG, van der Eijk AA, et al. Neuralgic amyotrophy and hepatitis E
virus infection. Neurology 2014;82:498–503.
10. van den Berg B, van der Eijk AA, Pas SD, et al. Guillain-Barré syndrome associated
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